Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting Peptide.
CD45
COVID-19
PBMC
Src family of tyrosine kinases
immunosuppression
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
03
2021
accepted:
09
07
2021
entrez:
20
8
2021
pubmed:
21
8
2021
medline:
21
8
2021
Statut:
epublish
Résumé
CD45, the predominant transmembrane tyrosine phosphatase in leukocytes, is required for the efficient induction of T cell receptor signaling and activation. We recently reported that the CD45-intracellular signals in peripheral blood mononuclear cells (PBMCs) of triple negative breast cancer (TNBC) patients are inhibited. We also reported that C24D, an immune modulating therapeutic peptide, binds to CD45 on immune-suppressed cells and resets the functionality of the immune system via the CD45 signaling pathway. Various studies have demonstrated that also viruses can interfere with the functions of CD45 and that patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are immune-suppressed. Given the similarity between the role of CD45 in viral immune suppression and our findings on TNBC, we hypothesized that the C24D peptide may have a similar "immune-resetting" effect on PBMCs from COVID-19 patients as it did on PBMCs from TNBC patients. We tested this hypothesis by comparing the CD45/TCR intracellular signaling in PBMCs from ten COVID-19 patients vs. PBMCs from ten healthy volunteers. Herein, we report our findings, demonstrating the immune reactivating effect of C24D via the phosphorylation of the tyrosine 505 and 394 in Lck, the tyrosine 493 in ZAP-70 and the tyrosine 172 in VAV-1 proteins in the CD45 signaling pathway. Despite the relatively small number of patients in this report, the results demonstrate that C24D rescued CD45 signaling. Given the central role played by CD45 in the immune system, we suggest CD45 as a potential therapeutic target.
Identifiants
pubmed: 34414199
doi: 10.3389/fmed.2021.675963
pmc: PMC8369232
doi:
Types de publication
Journal Article
Langues
eng
Pagination
675963Informations de copyright
Copyright © 2021 Alon, Paitan, Robinson, Ganor, Lipovetsky, Yerushalmi, Cohen and Raiter.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer OZ declared a past collaboration with several of the authors JL, AR, and RY to the handling editor.
Références
PLoS Pathog. 2013 Sep;9(9):e1003637
pubmed: 24068938
Cell Signal. 2018 May;45:132-144
pubmed: 29410283
Sci Signal. 2019 Oct 22;12(604):
pubmed: 31641081
J Leukoc Biol. 2020 Jul;108(1):17-41
pubmed: 32534467
Aging (Albany NY). 2020 Oct 16;12(20):19867-19879
pubmed: 33065551
PLoS Pathog. 2011 Dec;7(12):e1002432
pubmed: 22174689
Viruses. 2015 Mar 23;7(3):1540-57
pubmed: 25807057
J Proteome Res. 2015 Jul 2;14(7):2963-75
pubmed: 26043137
Nat Commun. 2020 Nov 17;11(1):5859
pubmed: 33203833
Annu Rev Immunol. 2003;21:107-37
pubmed: 12414720
Cell Signal. 2010 Mar;22(3):339-48
pubmed: 19861160
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
J Innate Immun. 2011;3(4):344-54
pubmed: 21576922
Nat Commun. 2021 Mar 19;12(1):1724
pubmed: 33741972
J Dtsch Dermatol Ges. 2020 Aug;18(8):810-813
pubmed: 32743938
Nat Rev Immunol. 2018 Aug;18(8):485-497
pubmed: 29789755
EClinicalMedicine. 2020 Oct;27:100518
pubmed: 32864588
Immunity. 2007 Sep;27(3):421-3
pubmed: 17892852
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Nat Immunol. 2006 May;7(5):524-32
pubmed: 16582911
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):E4884-93
pubmed: 24218549
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Neoplasia. 2014 Sep;16(9):741-50
pubmed: 25246274
Front Immunol. 2012 Jun 12;3:155
pubmed: 22701458
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Gen Virol. 2003 Mar;84(Pt 3):657-663
pubmed: 12604818
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32353870
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Nat Immunol. 2018 Jul;19(7):733-741
pubmed: 29915297
Front Cell Infect Microbiol. 2019 Feb 12;9:25
pubmed: 30809511
Oncoimmunology. 2021 May 25;10(1):1929725
pubmed: 34104545
Immunol Lett. 2004 Jul 15;94(3):167-74
pubmed: 15275963
Nat Immunol. 2016 May;17(5):574-582
pubmed: 26998761